DALUPHAR
The computed 12-month bankruptcy probability of DALUPHAR is 1.2% (low). The 2023 annual accounts show equity of €185k and a net result of €11k. Equity is shrinking by ~3% per year across the filed fiscal years. Its solvency ranks better than 66% of 1069 sector peers (fiscal year 2023). The company has been active since 2003 and the Belgian State Gazette contains no insolvency or warning signals.
| Equity | €185k |
| Net result | €11k |
| Staff (FTE) | 2.1 |
| Better than sector | 66% |
Strong profile, led by stability.
All 5 axes are computed from data Checked has read.
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
Unlock the full score breakdown, per-year score history and the indicative credit limit from Kantoor S.
See plans →How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 39.1% | 23.1% | |
| Net result | €11k | €25k | |
| Equity | €185k | €132k | |
| Gross operating margin | €201k | €202k | |
| Staff costs | €174k | €151k |
| Fiscal year | 2023 |
|---|---|
| Deposit | verkort |
| Revenue | - |
| EBITDA | €27k |
| Net profit | €11k |
| Cash flow | €25k |
| Staff costs | €174k |
| Income taxes | €192 |
| Dividends | - |
| Total assets | €473k |
| Equity | €185k |
| Debt | €288k |
| of which ≤ 1y | €271k |
| of which > 1y | €17k |
| Working capital | €156k |
| Employees (FTE) | 2.1 |
| 2023 | |
|---|---|
| Current ratio | 1.58 |
| Quick ratio | 0.85 |
| Working capital ratio | 33.0% |
| Solvency | 39.1% |
| Debt / equity | 1.56 |
| Long-term debt ratio | 0.09 |
| Interest coverage | 17.82 |
| Gross margin | - |
| Net margin | - |
| ROA | 2.4% |
| ROE | 6.2% |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | - |
| Inventory turnover | - |
| Days inventory (DSI) | - |
| Line item | Code | 2023 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €473k |
| Fixed assets | 21/28 | €46k |
| Tangible fixed assets | 22/27 | €46k |
| Financial fixed assets | 28 | €80 |
| Current assets | 29/58 | €427k |
| Stocks & contracts in progress | 3 | €196k |
| Amounts receivable within one year | 40/41 | €68k |
| Cash & bank | 54/58 | €160k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €473k |
| Equity | 10/15 | €185k |
| Contributions / capital | 10/11 | €162k |
| Reserves | 13 | €60k |
| Accumulated profits (losses) | 14 | €-38k |
| Amounts payable | 17/49 | €288k |
| Amounts payable after one year | 17 | €17k |
| Amounts payable within one year | 42/48 | €271k |
| Trade debts payable within one year | 44 | €115k |
| Income statement | ||
| Gross operating margin | 9900 | €201k |
| Operating result | 9901 | €13k |
| Financial income | 75 | €32 |
| Financial charges | 65 | €2k |
| Result before taxes | 9903 | €12k |
| Income taxes | 67/77 | €192 |
| Net result for the period | 9904 | €11k |
| Result to be appropriated | 9905 | €11k |
Permanent representatives (1)
-
ERC PHARMALegal entityPermanent representative· perm. rep.: Mohammad KassasState Gazette act 24134334 (17-09-2024)Permanent representative17-09-2024 → present
Former directors (1)
-
Daniel TruytsDirectorState Gazette act 24134334 (17-09-2024)Former- → 17-09-2024
| NACE primary | Detailhandel in farmaceutische producten(47730) |
| Legal form | Public limited company(014) |
| Incorporation | 14-08-2003 |
| Status | Active |
| Postal code | 1070 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 21001A0504/00B003 | Brussels | 349 m² | 1 · 268 m² | 15.7 m · 4 fl. |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
24-03-2025 Change of permanent representative
Technical details
{
"events": [
{
"kind": "rep_rotation",
"role": "vaste_vertegenwoordiger",
"person": {
"rrn": null,
"name": "Mohamad KASSAS",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": "successor_conditional",
"via_org": {
"kbo": "1002.131.150",
"name": "ERC PHARMA SA",
"address": null,
"country": "BE",
"legal_form": "SA"
},
"statutory": null,
"compensated": null,
"effective_date": "2025-01-16",
"evidence_quote": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale a valid\u00E9 qu\u0027\u00E0 compter du 16 janvier 2025, Monsieur Mohamad KASSAS cesse son mandat de repr\u00E9sentant de la soci\u00E9t\u00E9 ERC PHARMA SA (BCE: 1002.131.150), elle-m\u00EAme administratrice de la soci\u00E9t\u00E9 DALUPHAR (BCE: 0860.093.852).",
"decharge_status": null,
"mandate_duration": null,
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": "immediate"
},
{
"kind": "rep_rotation",
"role": "vaste_vertegenwoordiger",
"person": {
"rrn": null,
"name": "Apostolos STATHOPOULOS",
"address": "Rue Belle-Vue 17, L-4974 DIPPACH",
"birth_date": "1971-06-16",
"profession": "administrateur-d\u00E9l\u00E9gu\u00E9",
"birth_place": null
},
"reason": null,
"subkind": "successor_conditional",
"via_org": {
"kbo": "1002.131.150",
"name": "ERC PHARMA S.A.",
"address": null,
"country": "BE",
"legal_form": "SA"
},
"statutory": null,
"compensated": null,
"effective_date": "2025-01-16",
"evidence_quote": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale a valid\u00E9 qu\u0027\u00E0 compter du 16 janvier 2025, Monsieur Apostolos STATHOPOULOS, administrateur-d\u00E9l\u00E9gu\u00E9 de ERC PHARMA S.A., n\u00E9 le 16 juin 1971, demeurant Rue Belle-Vue 17, L-4974 DIPPACH, sera nomm\u00E9 repr\u00E9sentant permanent en remplacement de M. Mohamad KASSAS.",
"decharge_status": null,
"mandate_duration": null,
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": "Mohamad KASSAS",
"effective_date_qualifier": "immediate"
}
],
"notary": {
"name": null,
"firm_city": null,
"firm_name": null,
"office_city": null,
"is_associated": false
},
"act_meta": {
"language": "mixed",
"pub_date": "2025-03-24",
"filing_date": "2025-01-16",
"act_kind_objet": "Objet de l\u0027acte:"
},
"decisions": [
{
"body": "algemene_vergadering",
"date": "2025-01-16",
"unanimous": null
}
],
"is_correction": false,
"subject_company": {
"kbo": "0860.093.852",
"name_full": "DALUPHAR",
"legal_form": "Soci\u00E9t\u00E9 anonyme"
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "Apostolos STATHOPOULOS",
"org_rep_person_name": null,
"person_role_at_subject": "Administrateur d\u00E9l\u00E9gu\u00E9 et repr\u00E9sentant permanent"
},
"co_filed_documents": [],
"corrected_publication_numac": null
}17-09-2024 2 directors appointed, 1 resigning
- Mohammad Kassas, Vaste vertegenwoordiger
- Laila Mellaoui, Dagelijks bestuur
- Daniel Truyts, Bestuurder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Daniel Truyts",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": null,
"via_org": null,
"statutory": null,
"compensated": null,
"effective_date": null,
"evidence_quote": "het ontslag van Daniel Truyts als Bestuurder en Gedelegeerd Bestuurder",
"decharge_status": null,
"mandate_duration": null,
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
},
{
"kind": "director_in",
"role": "vaste_vertegenwoordiger",
"person": {
"rrn": null,
"name": "Mohammad Kassas",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": null,
"via_org": {
"kbo": "1002.131.150",
"name": "ERC PHARMA",
"address": null,
"country": null,
"legal_form": null
},
"statutory": null,
"compensated": null,
"effective_date": null,
"evidence_quote": "de benoeming in de vacante functies van ERC PHARMA, ondernemingsnummer 1002.131.150, vertegenwoordigd door zijn vaste vertegenwoordiger Mohammad Kassas",
"decharge_status": null,
"mandate_duration": null,
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
},
{
"kind": "delegation_dagelijks_bestuur_in",
"role": "dagelijks_bestuur",
"person": {
"rrn": null,
"name": "Laila Mellaoui",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": null,
"via_org": {
"kbo": null,
"name": "ADMINCO SCS",
"address": "Alsembergsesteenweg 999 te 1180 Brussel",
"country": "BE",
"legal_form": null
},
"statutory": null,
"compensated": null,
"effective_date": null,
"evidence_quote": "De Buitengewone Algemene Vergadering verleent voimacht aan ADMINCO SCS Alsembergsesteenweg 999 te 1180 Brussel vertegenwoordidge door Laila Mellaoui, met de mogelijkheid van indeplaatsstelling om alle mogelijke formalitelten te vervullen betreffende neerleggingen en/of verklaringen op het ondernemin",
"decharge_status": null,
"mandate_duration": {
"kind": "indefinite",
"value": null
},
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
}
],
"notary": {
"name": null,
"firm_city": null,
"firm_name": null,
"office_city": "Brussel",
"is_associated": false
},
"act_meta": {
"language": "nl",
"pub_date": "2024-09-17",
"filing_date": "2024-09-09",
"act_kind_objet": "Onderwerp akte:"
},
"decisions": [
{
"body": "buitengewone_algemene_vergadering",
"date": "2024-08-19",
"unanimous": true
}
],
"is_correction": false,
"subject_company": {
"kbo": "0860.093.852",
"name_full": "DALUPHAR",
"legal_form": "Naamloze vennootschap"
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "Laila Mellaoui",
"org_rep_person_name": null,
"person_role_at_subject": "Mandataris"
},
"co_filed_documents": [],
"corrected_publication_numac": null
}Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
| Legal nameNL | DALUPHAR |